The aim of this study is to identify HPV molecular signature in head and neck cancer to establish a new classification for positive human papillomavirus oropharyngeal tumor
OROPAP is a monocentric exploratory study with retrospective inclusion of patients. The retrospective study focus on patients who have had surgery for HPV-positive oropharyngeal tumors whose survival is at least 2 year. Frozen and or FFPE biopsies of these tumors and frozen blood samples are available via the HEGP biological resources platform. The HPV molecular signatures will be identified by the capture-HPV technique. For each patient, clinical-anatomo-pathological data such as tumor size, tumor stage, presence or absence of metastasis, histological stage, different treatment lines and 2-years survival data will be collected through the use of data warehouse available on the HEGP.
Study Type
OBSERVATIONAL
Enrollment
66
Hôpital Européen Georges Pompidou
Paris, Île-de-France Region, France
Description the HPV molecular signatures identified by the Capture-HPV technique and comparison of these signatures with those already described in the classification described in the Holmes et al. in the cervix
Establish a new classification based on HPV molecular signature for positive human papillomavirus oropharyngeal tumor
Time frame: 18 months
Quantification of HPV circulating tumoral DNA in peripheral blood by droplet based digital PCR
Find in the peripheral blood of patients, the presence of circulating tumoral HPV DNA (ctDNA) by droplet based digital PCR and when it is possible compare chromosomal insertion patterns of HPV ct DNA as those found in tumors
Time frame: 18 months
Correlate identified HPV molecular signature with clinical-anatomo-pathological data.
Look for an association between the presence of specific HPV molecular signatures and clinical-anatomo-pathological data.
Time frame: 18 months
Number of Death of any cause, or eventual relapse
Look for an association between the presence of these molecular signatures and the survival of patients.
Time frame: 18 months
Ratio of the number of copies of viral genes to the number of cells
Measure the viral load of HPV in the tumor.
Time frame: 18 months
Precise description of HPV insertion localisation in human genome when HPV is integrated
Identify disrupted metabolic pathways in tumor cells.
Time frame: 18 months
Description of new HPV viral variants based on complete HPV genome sequencec obtained by Capture-HPV coupled with NGS
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Analyze of complete viral genomes and identify potential variants through sequencing data analysis
Time frame: 18 months